Shennon Biotechnologies is a technology company.
Shennon Biotechnologies has raised $13.0M across 1 funding round.
Shennon Biotechnologies has raised $13.0M in total across 1 funding round.
Shennon Biotechnologies is a biotechnology company developing immunotherapies for solid tumors using a proprietary ultra-high-throughput single-cell platform that functionally profiles millions of immune cells to identify rare, effective targets like TCRs or antibodies.[1][2][3] Founded in 2021 and based in San Francisco, it serves the healthcare sector focused on cancer treatment by addressing bottlenecks in immunotherapy development, enabling more precise and efficient therapies; the company has raised $13 million in seed funding and formed partnerships with clinical institutes for patient data analysis.[1][3]
Shennon Biotechnologies was founded in 2021 by Li Sun, PhD, who serves as CEO; Sun previously worked as a venture capitalist at Foundation Capital and Bessemer Venture Partners and holds a PhD in Applied Physics from Harvard University.[2] The idea emerged from advancing single-cell analysis technologies, building on expertise in physics and immunology to create a platform that profiles immune cell-antigen interactions at scale in hours, a significant leap for target discovery.[1][2][3] Early traction includes demonstrating the platform's ability to locate rare, activated T cells over 1.5 years post-founding, securing seed funding in March 2023 from investors like DCVC, AV8 Ventures, and Foundation Capital, and partnering with clinical institutes.[1][3][4]
Shennon rides the wave of next-generation immunotherapy, particularly for solid tumors where current treatments struggle due to tumor heterogeneity and immune evasion, by accelerating functional target discovery at single-cell resolution.[1][2] Timing aligns with surging demand for precision cell therapies post-CAR-T successes in blood cancers, amid market forces like advancing single-cell sequencing, AI-driven antigen prediction, and billions in VC flowing to oncology biotech.[1][4] It influences the ecosystem by partnering with clinical institutes for real-world data, potentially de-risking pipelines for investors like DCVC, and enabling scalable therapies that could expand immunotherapy beyond liquid tumors.[1][3][4]
Shennon is poised to advance its solid tumor pipeline toward clinical candidates, leveraging seed funding to scale target identification and expand into autoimmune diseases.[1][2] Trends like multimodal single-cell omics, AI integration for receptor design, and manufacturing scale-up will shape its path, amplifying its platform's edge in a $100B+ immuno-oncology market. Its influence may grow through more partnerships and follow-on funding, positioning it as a key engine for transformative, targeted therapies—echoing its mission to manipulate cells at single-cell precision for human disease breakthroughs.[2][3]
Shennon Biotechnologies has raised $13.0M in total across 1 funding round.
Shennon Biotechnologies's investors include 20VC, Anti fund, Astir Ventures, AV8 Ventures, Banana Capital, Bessemer Venture Partners, Buckley Ventures, James Hardiman, Matt Ocko, DCVC (Data Collective), Dragonfly Capital Partners, Foundation Capital.
Shennon Biotechnologies has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Seed in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $13.0M Seed | 20VC, Anti fund, Astir Ventures, AV8 Ventures, Banana Capital, Bessemer Venture Partners, Buckley Ventures, James Hardiman, Matt Ocko, DCVC (Data Collective), Dragonfly Capital Partners, Foundation Capital, Founders Fund, Insight Partners, Kepler Operator’s Fund, Khosla Ventures, Kleiner Perkins, Long Journey Ventures, Pareto Holdings, True Ventures, Uncorrelated Ventures, Jaan Tallinn, Josh Mohrer, Kunal Shah, Louis Beryl, Mei Z., Scott Banister, Shervin Pishevar |